Amarin Presents New REDUCE-IT Data and Research on EPA's Effects on Lipoprotein(a) at ACC 2026

Findings highlight potential benefits of icosapent ethyl in high-risk cardiovascular patients

Mar. 16, 2026 at 12:40pm

Got story updates? Submit your updates here. ›

Amarin Corporation announced that additional REDUCE-IT patient subgroup analysis and data on the mechanistic effects of eicosapentaenoic acid (EPA) on lipoprotein(a) oxidation will be presented at the American College of Cardiology's Annual Scientific Session & Expo in New Orleans. The presentations will cover the efficacy of icosapent ethyl in patients at extreme cardiovascular risk and in vitro research on EPA's impact on lipoprotein(a) oxidation.

Why it matters

The new REDUCE-IT data and mechanistic research provide further insights into the potential cardiovascular benefits of icosapent ethyl, Amarin's prescription treatment approved for reducing risk in high-risk patients despite statin therapy. This information could help advance the understanding and use of this therapy to address the significant unmet need for additional cardiovascular risk reduction.

The details

The REDUCE-IT oral presentation will examine the efficacy of icosapent ethyl in a subgroup of patients at extreme cardiovascular risk, while the poster presentation will detail in vitro research on how EPA may inhibit the oxidation of lipoprotein(a), which is associated with increased cardiovascular risk. These findings build on the previously published primary results of the landmark REDUCE-IT cardiovascular outcomes trial.

  • The REDUCE-IT oral presentation is scheduled for March 29th at 12:30pm CST.
  • The lipoprotein(a) oxidation poster presentation is scheduled for March 28th at 11:00am CST.

The players

Amarin Corporation plc

A global pharmaceutical company committed to reducing the cardiovascular disease burden and advancing the science of cardiovascular care.

REDUCE-IT

A global cardiovascular outcomes study designed to evaluate the effect of Amarin's VASCEPA (icosapent ethyl) in adult patients with controlled LDL-C but persistent elevated triglycerides.

American College of Cardiology (ACC)

A professional medical society that provides education, research, and clinical guidance to cardiovascular healthcare providers to optimize patient care and disease prevention.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.